SCHEDULE 13G: BlackRock Discloses 5.7% Passive Stake in Tonix Pharmaceuticals

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.7% of Tonix Pharmaceuticals Holding Corp.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 420,448 shares of Tonix Pharmaceuticals Holding Corp. common stock.
• This ownership represents 5.7% of the total outstanding common stock of Tonix Pharmaceuticals.
• BlackRock holds sole voting power over 411,151 shares and sole dispositive power over 420,448 shares.
• The filing indicates a passive investment, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The filing was made by BlackRock as a parent holding company, with several of its subsidiaries identified as entities that may beneficially own 5% or more of the shares, including BlackRock Advisors, LLC and BlackRock Fund Advisors.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing disclosing a passive ownership stake, providing no positive or negative operational or financial news about the issuer.

Positives

• BlackRock, a major institutional investor, holding a significant stake (5.7%) could be viewed as a vote of confidence in Tonix Pharmaceuticals.
• The passive nature of the investment suggests it is held in the ordinary course of business, indicating a long-term investment perspective rather than an activist one.

Negatives

• The document does not present any negative information regarding Tonix Pharmaceuticals or BlackRock's investment.

Risks

• The document is an ownership disclosure and does not detail specific risks related to Tonix Pharmaceuticals' operations or financial health.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Tonix Pharmaceuticals' future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a passive investment intent. This filing signals BlackRock's significant, but non-activist, stake in Tonix Pharmaceuticals, a common practice for large asset managers holding diversified portfolios.

Comparison to Industry Standards

• This filing is a standard disclosure for institutional investors crossing the 5% ownership threshold.
• BlackRock, as one of the world's largest asset managers, routinely files such disclosures across numerous companies as part of its investment activities.
• The document does not provide specific comparable companies, projects, or results to assess against broader industry benchmarks.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like BlackRock could be perceived positively, potentially increasing investor confidence and liquidity.
• Management: The passive nature of the investment suggests BlackRock is not seeking to influence management or control, allowing current management to continue their strategic direction without immediate activist pressure.

Next Steps

• The document does not specify any future actions or milestones for Tonix Pharmaceuticals or BlackRock's investment strategy.

Key Dates

Keywords

Tonix Pharmaceuticals Holding Corp., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, TNXP